Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash from Operations: 2012-2025

Historic Cash from Operations for CorMedix (CRMD) over the last 10 years, with Sep 2025 value amounting to $30.9 million.

  • CorMedix's Cash from Operations rose 326.06% to $30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.0 million, marking a year-over-year increase of 235.34%. This contributed to the annual value of -$50.6 million for FY2024, which is 31.78% down from last year.
  • Latest data reveals that CorMedix reported Cash from Operations of $30.9 million as of Q3 2025, which was up 2.88% from $30.0 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Cash from Operations ranged from a high of $30.9 million in Q3 2025 and a low of -$17.3 million during Q1 2024.
  • For the 3-year period, CorMedix's Cash from Operations averaged around $2.4 million, with its median value being -$8.0 million (2023).
  • As far as peak fluctuations go, CorMedix's Cash from Operations slumped by 309.81% in 2021, and later spiked by 326.06% in 2025.
  • CorMedix's Cash from Operations (Quarterly) stood at -$5.9 million in 2021, then decreased by 4.86% to -$6.2 million in 2022, then crashed by 54.11% to -$10.4 million in 2023, then plummeted by 66.54% to -$5.6 million in 2024, then spiked by 326.06% to $30.9 million in 2025.
  • Its last three reported values are $30.9 million in Q3 2025, $30.0 million for Q2 2025, and $19.7 million during Q1 2025.